Mbale Clinical Research Institute LIMITED

Mbale Clinical Research Institute LIMITED, operating as Clinical Research, is a Uganda-based clinical research organization that receives federal funding exclusively as a sub-recipient on National Institutes of Health grants managed through the Department of Health and Human Services. The vendor holds no prime contracts or prime grants; all three of its tracked federal awards are sub-grants flowing from Children's Hospital Medical Center.

Mbale Clinical Research Institute is a corporate entity classified as a private educational institution and non-profit organization, headquartered in Mbale, Uganda. The vendor does not hold set-aside certifications in the source material and competes for federal work through subaward relationships rather than as a direct prime applicant.

All three sub-grants fund the same research program — Realizing Effectiveness Across Continents with Hydroxyurea (REACH), a Phase I/II pilot study investigating hydroxyurea treatment for children with sickle cell anemia. Awards were issued on January 8, 2024 ($558 thousand combined obligated across all three sub-grants), November 15, 2024, and January 16, 2026, with Children's Hospital Medical Center serving as the prime grantee and Mbale Clinical Research Institute providing on-site clinical research capacity. The vendor's sole customer agency is the National Heart Lung and Blood Institute within NIH, accounting for 100% of tracked awards.

Activity is limited: two sub-awards in 2024 and one in early 2026, with no indication of broader federal customer relationships or vehicle positions. The vendor's federal footprint appears confined to this single grant program within NHLBI's pediatric sickle cell disease research portfolio, with Mbale serving as the international clinical research site supporting the U.S.-based prime institution's research objectives.